単一核RNAシーケンシングのためのマウス交感神経節のバーコード化抗体による低入力核単離および多重化

Executive Industry Relevance

Single-nucleus RNA sequencing of low-input mouse sympathetic ganglia enables high-resolution molecular profiling of neuronal and non-neuronal cell types relevant to cardiac innervation. This protocol supports multiplexed sample analysis and long-term preservation, addressing key bottlenecks in nervous system target validation and mechanistic de-risking for cardiovascular disease models. The approach enhances predictive confidence at the discovery and preclinical interface for neuro-cardiac research portfolios.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables molecular characterization of sympathetic ganglia in both healthy and disease states.
• Supports functional target validation by resolving neuronal, glial, and endothelial cell populations.
• Facilitates mechanistic de-risking for neuro-cardiac therapeutic hypotheses.
• Improves predictive confidence for prioritizing targets in autonomic nervous system research.

Screening & Assay Development

• Provides validated nuclei isolation and barcoding workflows for reproducible sample multiplexing.
• Delivers quantitative, cell-type-resolved transcriptomic outputs for downstream assay development.
• Enables scalable preparation of high-quality nuclei libraries for screening platforms.
• Supports reliable evaluation of compound effects on diverse ganglionic cell types.

Translational & Preclinical Research

• Aligns molecular profiling with disease-relevant models of cardiac innervation and remodeling.
• Maintains sample integrity for longitudinal and multi-cohort studies.
• Facilitates continuity from discovery through preclinical validation in neuro-cardiac pipelines.
• Supports risk-adjusted advancement decisions based on cell-type-specific transcriptomic data.

Pipeline & Workflow Integration

This protocol integrates into the discovery-to-preclinical continuum for neuro-cardiac research, enabling multiplexed, quantitative analysis of sympathetic ganglia at key inflection points.

• Discovery Biology: Supports hypothesis testing and pathway clarification in cardiac autonomic regulation.
• Screening: Provides reproducible nuclei isolation and barcoding for assay-ready sample preparation.
• Analytics: Delivers quantitative transcriptomic readouts and cell-type clustering for comparative analyses.
• Translational Research: Enables alignment with disease models and biomarker discovery in cardiac innervation studies.
• Enterprise Reuse: Establishes a reusable workflow for profiling ganglia from multiple organs and experimental conditions.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in neuro-cardiac target validation.
• Operational Value: Standardizes nuclei isolation, barcoding, and multiplexing for scalable, reproducible workflows.
• Strategic Value: Improves go/no-go decisions and capital efficiency by enabling robust, multi-sample analyses.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of neuro-cardiac therapeutic programs.

Implementation Considerations

• Requires expertise in dissection, nuclei isolation, and single-nucleus sequencing workflows.
• Needs access to specialized equipment such as swinging bucket centrifuges and droplet-based sequencing platforms.
• Demands rigorous cross-team standardization for sample handling and barcoding procedures.
• Adaptable to other ganglia and organ systems with protocol optimization.
• Dependent on high-quality nuclei preparation and library QC for reliable downstream analysis.

Biopharma FAQs